Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Sky Labs' CART-I ring – described as a cardio tracker – achieved 84.6% sensitivity compared to 69.1% for the Apple Watch, ...

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

Several ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety, and efficiency in healthcare.

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

defined as 12-month freedom from a documented 30-second episode of Afib/atrial flutter/atrial tachycardia, failure of pulmonary vein isolation (PVI), cardioversion, antiarrhythmic drug use ...

Boston Scientific today shared new clinical data supporting multiple therapies at the Heart Rhythm Society (HRS) 2025 Meeting ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...